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2001 U.S. dollars, then compared and contrasted. RESULTS:
Thirty studies were identiﬁed and reviewed. Seventeen assessed
diagnostic modalities: education and screening (6): dissection
and biopsy (3), follow-up/monitoring (2), chest X-ray (3), CT
and PET scan (3), while 13 evaluated treatments: surgery 
(3), adjuvant interferon (IFN-a) (9), and chemotherapy (1).
Melanoma education and screening programs appears to be cost-
saving or to have CE ratios <$50,000 per QALY saved. Of the
diagnostic, monitoring, and risk stratiﬁcation methods, physical
examination appears more cost-effective than chest x-rays,
abdominal ultrasound, CT scans, PET scans, and liver function
tests. The CE of therapeutic options depends on disease stage,
comorbidity, and other factors. All nine IFN-a studies across
multiple countries and research designs consistently present
favorable CE ratios, which improve as study time horizon is
extended. Among other therapies, Mohs micrographic surgery
appears more cost-effective than surgical excision and resection.
Radiosurgery combined with radiotherapy also appears to be
cost-effective compared to radiotherapy alone in at least some
subset of patients. Finally, the CE of experimental treatment such
as isolated limb perfusion, vaccines, and gene therapies, has not
been studied. CONCLUSIONS: The literature provides valuable
information to policy makers seeking to reduce the economic
burden of melanoma, most notably with respect to physical
examination and interferon. As new diagnostic and therapeutic
modalities become available, research is needed on their eco-
nomic value.
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SERVICE (NHS) PERSPECTIVE
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OBJECTIVES: Results from the ATAC trial indicated that anas-
trozole was superior to tamoxifen in terms of disease free sur-
vival in the adjuvant treatment of postmenopausal women with
hormone receptor-positive (HR+) EBC. Using updated 47-month
data (Cancer 2003;98:1802–10), we calculated the direct
medical costs and incremental cost effectiveness ratio (ICER) per
life year gained (LYG) for managing this group for anastrozole
compared with tamoxifen within the UK NHS setting.
METHODS: Using the updated ATAC data, we developed a
probabilistic Markov model, which projected outcomes for both
anastrozole and tamoxifen to 25 years (lifetime horizon) by
extrapolating pooled Kaplan-Meier curves. General mortality
data were obtained from UK national statistics. It was assumed
that anastrozole and tamoxifen would be given for ﬁve years
maximum and that recurrence rates after this treatment period
would be equivalent in the two groups—a conservative
approach. Resource utilization data associated with treating
adverse events were obtained from published literature. Other
resource utilization data were estimated from interviews with six
UK physicians. Unit costs in GBP were obtained from 2002 NHS
reference costs and 2003 drug costs (BNF). Costs and beneﬁts
were discounted at 6% and 1.5%, respectively. RESULTS: Con-
sidering a cohort of 1000 patients modeled for 25 years, anas-
trozole was estimated to lead to 184 discounted LYG at an
additional cost of £2.1 million. Consequently, the discounted
ICER of anastrozole compared with tamoxifen was estimated to
be £11,747/LYG (95% CI £1,946–£21,984). Furthermore,
acceptability curves showed that the estimated cost/LYG at 25
years was <£20,000 with a probability >90%. The result com-
pared favorably with commonly accepted thresholds for cost-
effectiveness of other cancer drugs and was robust to all para-
meters (including adverse events) tested in sensitivity analyses.
CONCLUSIONS: Based on these ﬁndings, anastrozole should be
a cost-effective alternative to tamoxifen for the adjuvant treat-
ment of postmenopausal women with HR+ early breast cancer.
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COST-EFFECTIVENESS (CE) ANALYSIS OF INTERFERON-
ALPHA IN HIGH-RISK MELANOMA PATIENTS
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OBJECTIVES: We examined the cost-effectiveness (CE) of treat-
ment with adjuvant high-dose Interferon-alpha (IFN-alpha)
given in melanoma patients at high-risk for recurrence from a
program perspective. METHODS: A continuous-time Markov
model with nine health states (no evidence of disease, local-
regional recurrence, ﬁrst salvage local-regional recurrence,
second local-regional recurrence, ﬁrst distant recurrence, sal-
vaged distant recurrence, second distant recurrence, death from
melanoma, and death of other causes) was designed to assess the
CE of IFN-alpha treatment compared to no adjuvant treatment.
Estimates of costs (inﬂated to 2002), utilities for health states,
and treatment beneﬁts were retrieved from published literature.
A non-informative prior was used for the survival parameters
and patient-level data was simulated with survival parameters
retrieved from published literature. To quantify the tradeoff
between IFN-alpha toxicity and survival, net beneﬁts were 
calculated as potential savings in quality-adjusted life years
(QALYs). Average costs and beneﬁts were derived from the inte-
gration over unknown patient parameters. The posterior incre-
mental cost-effectiveness ratio (ICER) was then simulated as the
difference in average cost divided by the difference in average
effectiveness. RESULTS: The posterior mean estimate of the
incremental costs of the IFN-alpha was $37,000 and the poste-
rior mean estimate of the incremental beneﬁts was 0.75 QALY.
The estimated posterior mean ICER was $50,300/QALY with
standard deviation $183/QALY. The acceptability curve (CEAcc)
shows that the probability that IFN-alpha treatment will lead to
improved life expectancy is one. CONCLUSIONS: IFN-alpha
treatment is more costly and more effective based on simulated
patient-level data. With patient-level data, we will be able to
provide information on the variability of model parameters and
produce the acceptability curve using the current model.
RESPIRATORY DISORDERS AND INFECTIONS
RI1
THE EFFECT OF PRESCRIPTION DRUG COVERAGE ON THE
COST OF CARE FOR MEDICARE BENEFICIARIES WITH
ASTHMA
Atherly A,Williams S, Redd S
Centers for Disease Control, Atlanta, GA, USA
OBJECTIVE: To investigate the cost of asthma care for enrollees
in the Medicare program and the effect of voluntary outpatient
prescription drug coverage on Medicare covered asthma expen-
ditures. METHODS: Data were drawn from the 2001 Medicare
Current Beneﬁciary Survey, a nationally representative sample of
the Medicare population, which includes data on health care
expenditures and individual characteristics such as health status.
Sample size was 13,998, including 1,310 persons with asthma.
We used regression analysis to examine differences in expendi-
tures between those with and without asthma, controlling for
other chronic illnesses, self-rated health, age, gender, activity of
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daily living limitations, supplemental insurance coverage and
region. We also examined whether prescription drug coverage
modiﬁed the difference in expenditures among enrollees with
asthma. RESULTS: Medicare beneﬁciaries with asthma had
higher mean Part A expenditures ($4412 versus $2744), longer
average hospital stays (3.53 days versus 1.82), and higher 
Part B expenditures ($3688 versus $2547) than those without
asthma. In regression analysis, asthma increased mean Part A
expenditures by $850 and Part B expenditures by $551. Outpa-
tient prescription drug coverage decreased Part B spending on
persons with asthma by $446, but increased Part B spending by
$243 for those without asthma. Prescription drug coverage had
no effect on either Part A expenditures or the number of days
spent in the hospital for either those with or those without
asthma. CONCLUSIONS: Asthma increases expenditures in the
Medicare program, but the increase is moderated by outpatient
prescription drug coverage. This suggests that spending increases
associated with the new Medicare prescription drug beneﬁt may
be mitigated by reductions in spending on chronic illnesses such
as asthma. As the new drug beneﬁt is designed, attention should
be focused on the identiﬁcation of medications that reduce
overall Medicare spending to insure that they are covered by
drug plans.
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OBJECTIVE: To estimate the annual excess cost of chronic
obstructive pulmonary disease (COPD) to a large managed-care
plan. METHODS: This study employed a retrospective, matched
cohort design and administrative claims data from the large
multi-state managed care database. Patients selected were 35+
years of age, with a diagnosis of COPD in 2001, and eligible for
medical and pharmacy beneﬁts as of January 1, 2001. The com-
parison cohort consisted of patients without COPD matched on
age, gender, geographic region, and insurance coverage type. The
excess cost of COPD was estimated as the difference in mean
health plan payments between the COPD and comparison
cohorts during 2001. Multivariate techniques were employed to
assess the contribution of mortality and comorbidity to excess
costs. RESULTS: A total of 61,527 patients with COPD met
study inclusion criteria, a prevalence of approximately 9%.
Approximately 12% were diagnosed with emphysema, 25%
with chronic bronchitis, and 63% with unclassiﬁed chronic
airway obstruction. COPD patients and their matched controls
(n = 61,527) averaged 71 years of age and 50% were female.
Charlson comorbidities, especially vascular disease and cancer,
were more common in the COPD cohort. The utilization of most
types of services was signiﬁcantly (P < 0.001) higher in the COPD
group, including hospitalizations (43% vs. 14%), emergency
room visits (47% vs. 21%), and home health-care services (28%
vs. 8%). The annual per-patient excess cost of COPD from the
health plan perspective was estimated to be approximately
$7900 ($11,350 for the COPD cohort minus $3450 for the
control cohort), 58% of which was due to hospitalizations. The
higher burden of comorbidity and mortality in the COPD cohort
accounted for about 40% of the observed difference in excess
costs. CONCLUSIONS: The excess cost of COPD is substantial.
Acute hospitalizations and greater comorbidity burden explain
a large portion of these excess costs.
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OBJECTIVE: Recent guidelines have recommended that children
aged 6–24 months should be immunized with inﬂuenza vaccine
to protect against inﬂuenza. Our objective was to evaluate health
outcomes and costs to society of inﬂuenza vaccination on
inﬂuenza and acute otitis media infection in an otherwise healthy
population of 6–24 month old infants. METHODS: Based 
on published and unpublished data, a decision analytical model
comparing two strategies: children vaccinated with inactivated
inﬂuenza vaccine and children not vaccinated children has been
developed. The clinical pathway predicted the probability of
becoming infected with inﬂuenza, developing acute otitis media
in conjunction with inﬂuenza or alone. Health outcomes used in
this model included days of illness as well as days of paid
employment missed by primary caregiver. Costs incorporated
into the model included both direct and indirect costs including
cost of vaccination, pharmaceutical costs of treatment of infec-
tion, hospitalization, and caregiver employment income lost.
Robustness of results was tested by univariate and multivariate
sensitivity analysis. The model was used to simulate the results
for an otherwise health population comparing vaccination to
non-vaccination strategy of care. RESULTS: Vaccination pro-
grams had lower cost and better health outcomes when com-
pared to non-vaccination programs. Vaccinated children had an
expected cost to society of $329.51 with 2.29 expected days of
illness and 1.93 days of work missed by the primary caregiver.
Non-vaccinated children had an expected cost of $393.78 with
3.97 expected days of illness and 2.63 days of work missed by
the primary caregiver. Univariate and multivariate sensitivity
analysis showed these results to be robust in upholding vaccina-
tion as a cost effective alternative to no vaccination over a wide
range of assumptions. CONCLUSION: Immunization with inac-
tivated inﬂuenza vaccine is a cost effective treatment in reducing
the incidence of both inﬂuenza and acute otitis media for chil-
dren aged 6–24 months.
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OBJECTIVE: This study evaluates the projected cost-
effectiveness of antiviral treatments (amantadine or oseltamivir)
with and without the use of inﬂuenza rapid tests in children.
METHODS: A decision tree was developed to predict costs and
health effects of 5 strategies: no antiviral treatment, empirical
treatment with amantadine, empirical treatment with
oseltamivir, testing then treatment with amantadine, and testing
then treatment with oseltamivir. The target population was strat-
iﬁed by age (6–23mos, 2yrs, 3–4yrs, 5–11yrs, and 12–17yrs)
and risk status (high or low risk for inﬂuenza-related complica-
tions). Probabilities and costs (direct and opportunity) for
uncomplicated inﬂuenza, inﬂuenza-like illness, outpatient visits,
hospitalizations, deaths, effectiveness of antiviral treatments,
treatment adverse events, and characteristics of inﬂuenza rapid
tests were based on primary and secondary data. Quality adjust-
